Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Oct 18

    Regeneron Announces Upcoming Investor Conference Presentations
  • Oct 10

    Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019


  • Jefferies 2019 London Healthcare Conference
    Nov 20
    9:00 AM EST
    Nov 20, 2019 | 9:00 AM EST

  • Credit Suisse 28th Annual Healthcare Conference
    Nov 12
    10:00 AM EST
    Nov 12, 2019 | 10:00 AM EST

  • Regeneron Pharmaceuticals Q3 2019 Earnings Conference Call
    Nov 5
    8:30 AM EST
    Nov 5, 2019 | 8:30 AM EST